Literature DB >> 22495321

The genetic architecture of multiple myeloma.

Gareth J Morgan1, Brian A Walker, Faith E Davies.   

Abstract

Based on the clinical features of myeloma and related malignancies of plasma cells, it has been possible to generate a model system of myeloma progression from a normal plasma cell through smouldering myeloma to myeloma and then plasma cell leukaemia. Using this model system we can study at which points the genetic alterations identified through whole-tumour molecular analyses function in the initiation and progression of myeloma. Further genetic complexity, such as intraclonal heterogeneity, and insights into the molecular evolution and intraclonal dynamics in this model system are crucial to our understandings of tumour progression, treatment resistance and the use of currently available and future treatments.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22495321     DOI： 10.1038/nrc3257

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  109 in total

1.  Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes.

Authors:  V M Braga; M Betson; X Li; N Lamarche-Vane
Journal:  Mol Biol Cell       Date:  2000-11       Impact factor: 4.138

2.  High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.

Authors:  Kevin D Boyd; Brian A Walker; Christopher P Wardell; Fiona M Ross; Walter M Gregory; Faith E Davies; Gareth J Morgan
Journal:  Leuk Lymphoma       Date:  2010-09-21

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

Review 5.  Cytoplasmic dynein.

Authors:  Victoria J Allan
Journal:  Biochem Soc Trans       Date:  2011-10       Impact factor: 5.407

6.  Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.

Authors:  Masaharu Akiyama; Teru Hideshima; Masood A Shammas; Toshiaki Hayashi; Makoto Hamasaki; Yu-Tzu Tai; Paul Richardson; Sergei Gryaznov; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

Authors:  Jotin Marango; Manabu Shimoyama; Hitomi Nishio; Julia A Meyer; Dong-Joon Min; Andres Sirulnik; Yolanda Martinez-Martinez; Marta Chesi; P Leif Bergsagel; Ming-Ming Zhou; Samuel Waxman; Boris A Leibovitch; Martin J Walsh; Jonathan D Licht
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

8.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

Review 9.  Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

Authors:  David González; Mirjam van der Burg; Ramón García-Sanz; James A Fenton; Anton W Langerak; Marcos González; Jacques J M van Dongen; Jesus F San Miguel; Gareth J Morgan
Journal:  Blood       Date:  2007-07-18       Impact factor: 22.113

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307
View more
  349 in total

1.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

2.  In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Authors:  M Martínez-Moreno; M Leiva; N Aguilera-Montilla; S Sevilla-Movilla; S Isern de Val; N Arellano-Sánchez; N C Gutiérrez; R Maldonado; J Martínez-López; I Buño; J A García-Marco; P Sánchez-Mateos; A Hidalgo; A García-Pardo; J Teixidó
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

Review 3.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

5.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 6.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

7.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

8.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

9.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

Review 10.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.